CSPC and Flame Biosciences of the United States reached a cooperation agreement of over 600 million US dollars to promote the globalization of new bispecific antibodies

CSPC Announcement

CSPC Announcement

On August 17, CSPC announced that its subsidiary NovaRock Biotherapeutics Limited (NovaRock) had entered into a strategic cooperation and licensing agreement (the agreement) with Flame Biosciences, Inc.
(Flame Biosciences)
.

August 17, CSPC

According to the terms of the agreement, NovaRock will grant Flame Biosciences to develop, manufacture and commercialize its fully human anti-Claudin 18.
2 monoclonal antibody (NBL- 015) exclusive rights
.

NovaRock will also use its NovaTE bispecific antibody technology platform to collaborate with Flame Biosciences to discover and pre-clinically develop two new bispecific antibodies (together with NBL-015, collectively referred to as licensed products).

Claudin 18.
2 is a member of the claudin family and belongs to the tight junction protein class
.

Its expression in normal tissues is limited to gastric cell lineage and short-lived differentiated epithelial cells, while it is expressed in a variety of cancer types, including pancreatic cancer, gastric cancer, esophageal cancer, lung cancer and ovarian cancer

Previously published in Cancer research abstract, the use of NovaRock's proprietary antibody discovery and development platform successfully discovered and optimized the next generation of anti-claudin 18.
2 mAb, NBL-015
.

NBL-015 shows strong anti-tumor activity in vitro and in vivo

Immune pancreatic gastric NBL-015 has been the United States Food and Drug Administration Administration ( the FDA ) awarded orphan status recognized for treatment of pancreatic cancer and gastric cancer (including cancer of the esophagus gastric junction), the experimental new drug (IND) application has also been in It was approved by the US FDA in May 2021

Cai Jie et al.
analyzed the incidence and mortality trends of pancreatic cancer in China from 2005 to 2015 and found that the trend of changes in the crude incidence and mortality of pancreatic cancer in China from 2005 to 2015 was basically the same, and the incidence and mortality of pancreatic cancer in China rose steadily.

.

From 2005 to 2015, the overall incidence of pancreatic cancer has increased by an average of 2.

The announcement also stated that NovaRock will receive a down payment of US$7.
5 million and has the right to receive development milestone payments of up to US$172.
5 million if the development milestone event is reached
.

NovaRock is also entitled to receive sales milestone payments of up to US$460 million on the condition that the sales milestones are reached, and a percentage of the net sales of the licensed products in the region

NovaTE is a novel tumor antigen and CD-137 double antibody technology platform, which aims to selectively activate T cells with antigen experience in the tumor microenvironment
.

Its patented scaffold can maximize tumor cell participation and T cell activation, while minimizing the possibility of systemic adverse events

Flame Biosciences is an innovative pharmaceutical company headquartered in the United States.
The company focuses on the development and commercialization of transformative therapies for cancer and other inflammations
.

The strategic cooperation with Flame Biosciences not only accelerates the clinical development of the group's innovative drug pipeline in the global market, but also marks the group's significant progress in advancing its internationalization strategy

 

Reference materials:

1. CSPC : Voluntary Announcement-Entering into a strategic cooperation and licensing agreement with FLAME BIOSCIENCES
2. Analysis of Incidence and Mortality Trends of Pancreatic Cancer in China from 2005 to 2015

CSPC : Voluntary Announcement-Entering into a strategic cooperation and licensing agreement with FLAME BIOSCIENCES

CSPC Group:

Analysis of Incidence and Mortality Trends of Pancreatic Cancer in China from 2005 to 2015

Leave a message here